AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorOttawa Heart Institute Research Corporation

About this trial

Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.

Eligibility criteria

Qualifiers

Heart transplant

Age ≥18 years

Able to provide informed consent

Disqualifiers

Allergy or known intolerance to aspirin

Allergy or known intolerance to clopidogrel

Intracranial hemorrhage ≤14 days

Bleeding disorder

Trial design

Treatments tested in this trial

  • Placebo
  • aspirin
  • Clopidogrel

Treatment groups

135 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Ottawa Heart Institute Research Corporation

Lead sponsor

Canadian Institutes of Health Research (CIHR)

Collaborator